---
title: "Shandong Boyuan Pharmaceutical&Chemical Co.,Ltd (301617.SZ)"
type: "quote"
locale: "en"
url: "https://longbridge.com/en/quote/301617.SZ.md"
symbol: "301617.SZ"
name: "Shandong Boyuan Pharmaceutical&Chemical Co.,Ltd"
industry: "Specialty Chemicals"
---

# Shandong Boyuan Pharmaceutical&Chemical Co.,Ltd (301617.SZ)

| Item | Detail |
|------|--------|
| Industry | Specialty Chemicals |
| Location | CN Market |
| Website | [www.boyuanchemical.com](https://www.boyuanchemical.com) |

## Company Profile

Shandong Boyuan Pharmaceutical & Chemical Co., Ltd. engages in the research and development, production, and sale of fine chemicals in China. It operates in four segments: Iodine Derivatives, Industrial Catalysts (precious metals), Organosilicon Series, and Chemiluminescent Materials. The company of...

## Financial Score

> *Longbridge Financial Score™ — Proprietary multi-factor rating model by [Longbridge](https://longbridge.com). This score is independently calculated by Longbridge and is not affiliated with any third-party rating agency.*
> Updated: 2026-03-02T04:30:10.000Z

**Overall: B (0.27)**

**Industry**: Specialty Chemicals

| Metric | Value |
|--------|-------|
| Industry Ranking | 22 / 154 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Blend - Stocks in which the company has both growth and mature businesses.
- **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns.

### Score Analysis

**Style Score**: 

#### Growth Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 8.45% |  |
| Net Profit YoY | -16.43% |  |

#### Value Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| P/B Ratio | 5.73 |  |
| Dividend Ratio | 0.59% |  |


**Size Score**: 

#### Market Cap Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 9.68B |  |

#### Revenue Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue | 1.39B |  |


**Multi Score**: B

#### Profit Score: B

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | 13.10% | B |
| Profit Margin | 12.54% | B |
| Gross Margin | 20.59% | D |

#### Growth Score: B

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 8.45% | B |
| Net Profit YoY | -16.43% | D |
| Total Assets YoY | 62.68% | A |
| Net Assets YoY | 72.35% | A |

#### Cash Score: B

| Indicator | Value | Rating |
|-----------|-------|--------|
| Cash Flow Margin | 797.39% | B |
| OCF YoY | 8.45% | B |

#### Operating Score: A

| Indicator | Value | Rating |
|-----------|-------|--------|
| Turnover | 0.92 | A |

#### Debt Score: A

| Indicator | Value | Rating |
|-----------|-------|--------|
| Gearing Ratio | 9.93% | A |


```chart-data:radar
{
  "title": "Longbridge Financial Score - Shandong Boyuan Pharmaceutical&Chemical Co.,Ltd",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Profit",
      "grade": "B",
      "indicators": [
        {
          "name": "ROE",
          "value": "13.10%",
          "rating": "B"
        },
        {
          "name": "Profit Margin",
          "value": "12.54%",
          "rating": "B"
        },
        {
          "name": "Gross Margin",
          "value": "20.59%",
          "rating": "D"
        }
      ]
    },
    {
      "name": "Growth",
      "grade": "B",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "8.45%",
          "rating": "B"
        },
        {
          "name": "Net Profit YoY",
          "value": "-16.43%",
          "rating": "D"
        },
        {
          "name": "Total Assets YoY",
          "value": "62.68%",
          "rating": "A"
        },
        {
          "name": "Net Assets YoY",
          "value": "72.35%",
          "rating": "A"
        }
      ]
    },
    {
      "name": "Cash",
      "grade": "B",
      "indicators": [
        {
          "name": "Cash Flow Margin",
          "value": "797.39%",
          "rating": "B"
        },
        {
          "name": "OCF YoY",
          "value": "8.45%",
          "rating": "B"
        }
      ]
    },
    {
      "name": "Operating",
      "grade": "A",
      "indicators": [
        {
          "name": "Turnover",
          "value": "0.92",
          "rating": "A"
        }
      ]
    },
    {
      "name": "Security",
      "grade": "A",
      "indicators": [
        {
          "name": "Gearing Ratio",
          "value": "9.93%",
          "rating": "A"
        }
      ]
    }
  ]
}
```

### Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
|------|------|--------|--------|-----------|----------|------|--------|
| 01 | NHU (SZ.002001) | A | B | C | B | C | B |
| 02 | HCSC (SH.600378) | B | A | B | B | B | B |
| 03 | DING LONG (SZ.300054) | B | B | C | C | B | B |
| 04 | CAPCHEM (SZ.300037) | B | B | E | A | B | B |
| 05 | Cathay Biotech (SH.688065) | C | A | D | A | B | B |

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | 55.33 | 52/157 | 59.90 | 44.05 | 24.54 |
| PB | 5.73 | 128/157 | 6.35 | 4.97 | 3.13 |
| PS (TTM) | 6.94 | 109/157 | 7.71 | 6.07 | 3.89 |
| Dividend Yield | 0.60% | 51/157 | 1.13% | 0.80% | 0.62% |

## Institutional View

### Analyst Rating Distribution

> As of 2025-10-27T16:00:00.000Z

Total Analysts: **1**

| Rating | Count | Percentage |
|--------|-------|-----------|
| Buy | 1 | 100% |
| Overweight | 0 | 0% |
| Hold | 0 | 0% |
| Underweight | 0 | 0% |
| Sell | 0 | 0% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 70.62 |
| Highest Target | 125.00 |
| Lowest Target | 125.00 |

## References

- [Company Overview](https://longbridge.com/en/quote/301617.SZ/overview.md) - Shareholders, executives, business segments
- [Financials](https://longbridge.com/en/quote/301617.SZ/norm.md) - Income statement, balance sheet, cash flow, distribution plan
- [Topics & Discussions](https://longbridge.com/en/quote/301617.SZ/topics.md) - Community topics and discussions

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.